More than 4 million people have signed our petitions calling for lower prescription drug prices, and Sens. Blumenthal, Murphy and Sinema have responded.
Medicare Part D Spending on Top Brand Name Drugs Greatly Exceeds the Costs Associated with Drug Development
High and growing prescription drug prices will eventually affect all Americans in some way. Congress is currently considering proposals that will permit Medicare to negotiate with drug companies, as well as discourage price increases that exceed inflation.
Sens. Ben Cardin, Chris Van Hollen, Debbie Stabenow and Gary Peters respond to our petitions for Congress to lower prescription drug prices.
President Joe Biden stressed the need to get America’s skyrocketing prescription drug prices under control during an event Thursday at a Virginia community college.
We joined more than 90 unions, health care groups and advocacy organizations in sending letters to Senate Democrats urging them to lower prescription drug prices.
AARP testimony called on lawmakers to penalize drug companies that raise prices faster than inflation and allow Medicare to negotiate with drug companies for lower prices.
AARP New York met with Senate Majority Leader Chuck Schumer, handing him a petition signed by 283,000 New Yorkers demanding lower drug prices.
Despite the myriad of financial challenges facing patients and all Americans, many brand name drug companies have already increased the prices of their products in 2022.
AARP has a message for lawmakers considering a tax credit for the country’s 48 million family caregivers as part of the current budget reconciliation package: Don’t miss this opportunity.
It’s well known that prescription drug prices are skyrocketing in America. Price increases for brand name drugs have far exceeded the rate of inflation since at least 2006, according to AARP’s Rx Price Watch report. And the average annual cost for just one brand name drug taken on a chronic basis…
Search AARP Blogs